Pan-Cancer Analysis of the Prognostic and Immunological Role of TOMM40 to Identify Its Function in Breast Cancer

Yaqing Zhou ¹, Xing Wei ², Lijun Jia ¹

⁰Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong University, No.157 XiwuRoad, Xi'an, 710004, China.

Biochemical Genetics +

|

April 22, 2024

View abstract on PubMed

Summary

TOMM40, a mitochondrial autophagy-related gene, is a prognostic indicator for 21 cancers, including breast cancer. Its high expression correlates with poorer outcomes, suggesting it as a potential therapeutic target.

Area Of Science

Oncology
Molecular Biology
Genetics

Background

Breast cancer is a leading global malignancy in women.
Mitophagy plays a role in breast cancer prevention and treatment.
Individual mitochondrial autophagy-related genes (MARGs) roles in cancer are understudied.

Purpose Of The Study

To investigate the prognostic and biological significance of TOMM40, a MARG, in pan-cancer analysis.
To evaluate TOMM40 as a prognostic biomarker and potential therapeutic target in breast cancer.

Main Methods

Bioinformatics analysis including Kaplan-Meier survival analysis.
Gene Set Enrichment Analysis (GSEA) and functional enrichment analysis.
In vitro studies involving TOMM40 knockdown in breast cancer cells.

Main Results

TOMM40 was identified as a prognostic DEMARG (PDEMARG) in breast cancer.
High TOMM40 expression was linked to poorer prognosis in 21 cancer types.
TOMM40 knockdown inhibited breast cancer cell proliferation, migration, and invasiveness.
TOMM40 showed significant associations with immune infiltration and drug sensitivity across various cancers.

Conclusions

TOMM40 is a valuable prognostic biomarker across 21 cancers, including breast cancer.
TOMM40 may serve as a potential immunotherapeutic target for breast cancer treatment.
Further research into MARGs, particularly TOMM40, could offer new therapeutic strategies for breast cancer.

Keywords:

Immune Mitophagy Pan-cancer TNBC TOMM40